Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia

Cerebrospinal fluid (CSF) brain-derived tau (BD-tau) levels decreased with sodium selenate treatment in patients with Alzheimer's disease (AD).CSF BD-tau levels did not change with sodium selenate treatment in bvFTD.Baseline CSF BD-tau correlated with CSF total tau (t-tau) and phosphorylated tau-181 (p-tau181) in AD and behavioral variant frontotemporal dementia (bvFTD).Baseline serum and plasma BD-tau levels did not correlate with CSF BD-tau in bvFTD.CSF p-tau217 did not change with sodium selenate treatment in AD or bvFTD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Published
2025-04-01
DOI
https://doi.org/10.1002/dad2.70123
Citations
1
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia

Cassandra Marotta, Terence John O'Brien, Michael Turton, Fernando González‐Ortiz et al.
1 citations
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Dementia and Cognitive Impairment Research
1.47
article

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia

Cassandra Marotta, Terence John O'Brien, Michael Turton, Fernando González‐Ortiz, Benjamin Sinclair, Lucy E. Vivash, Henrik Zetterberg, Christopher M. Hovens, Kaj Blennow, Peter Harrison
article en
1 citations

Abstract

Cerebrospinal fluid (CSF) brain-derived tau (BD-tau) levels decreased with sodium selenate treatment in patients with Alzheimer's disease (AD).CSF BD-tau levels did not change with sodium selenate treatment in bvFTD.Baseline CSF BD-tau correlated with CSF total tau (t-tau) and phosphorylated tau-181 (p-tau181) in AD and behavioral variant frontotemporal dementia (bvFTD).Baseline serum and plasma BD-tau levels did not correlate with CSF BD-tau in bvFTD.CSF p-tau217 did not change with sodium selenate treatment in AD or bvFTD.

Alzheimer s & Dementia Diagnosis Assessment & Disease MonitoringVol. 17(2)
The Royal Melbourne Hospital (AU), The University of Melbourne (AU), Hong Kong Science and Technology Parks Corporation (HK), Sahlgrenska University Hospital (SE), Victorian Comprehensive Cancer Centre (AU), UK Dementia Research Institute (GB), National Hospital for Neurology and Neurosurgery (GB), Alfred Health (AU), University College London (GB), Monash University (AU), University of Gothenburg (SE)
U.S. Department of Defense, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Biogen, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, Royal Melbourne Hospital Neuroscience Foundation, EU Joint Programme – Neurodegenerative Disease Research, Australian Government, European Partnership on Metrology, National Institute for Health and Care Research, University College London, European Commission, Eisai, Hjärnfonden, Vetenskapsrådet, UK Dementia Research Institute, Epilepsy Society, National Institutes of Health, HORIZON EUROPE Framework Programme, Medical Research Council, National Health and Medical Research Council, UCB Pharma
Good health and well-being
Openalex Percentile: Top 19%
Dementia and Cognitive Impairment Research
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.